AstraZeneca Reports Q2 Earnings Beat On The Back Of A Diversified Drug Portfolio

AstraZeneca plc (NYSE: AZN) second-quarter earnings beat estimates as demand for its therapies centered on diabetes and cancer remained strong, with the drugmaker also working on a potential coronavirus vaccine.